|   In the News

Vigil Neuroscience launches with a $50M Series A and two former Amgen neuroscience candidates

After more than 20 years in the industry, Ivana Magovčević-Liebisch had done it all — except build a company from scratch. Then Bruce Booth at Atlas Venture mentioned a couple of TREM2 assets he was trying to snag from Amgen’s old neuroscience pipeline.

Read more.


  |   In the News

RNA startup Remix raises $81M from Atlas, Arch Venture

Local life sciences investor Atlas Venture is continuing its push into RNA therapies with a new company: Remix Therapeutics.

Read more.


  |   In the News

Startup Spotlight: Bullish on its asthma treatment, Kinaset forges ahead in unusual times

Launching a clinical trial for a drug intended to treat severe asthma during a respiratory pandemic — particularly one that seems to hit people with some types of asthma particularly hard — could be a risky move.

Read more.


  |   LifeSciVC

Biotech: The Featherweight Champion Of The Markets

By Bruce Booth, DPhil, Partner

Biotech punches way above its weight-class, and that’s never been more apparent than in this pandemic and the race for a COVID vaccine.

Read more.


  |   Press Release

Atlas Venture Welcomes Rajesh Devraj, PhD, as Venture Partner

Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, announced today that Rajesh (Raj) Devraj, PhD, is joining the firm as a venture partner. Devraj will be working with the Atlas team to identify and execute upon compelling opportunities for new biotechnology company creation.

Read more.